Skip to main content
. Author manuscript; available in PMC: 2014 Dec 28.
Published in final edited form as: J Control Release. 2013 Oct 2;172(3):1045–1064. doi: 10.1016/j.jconrel.2013.09.026

Fig. 1.

Fig. 1

Summary of phase III performance of selected drug carrier therapies compared to standard treatment. PFS: progression free survival; OS: overall survival; ORR: overall response rate. Data gathered from phase III trials [21], [22], [69], [106], [119], [122], [183], [184], [185].